National real-life impact of prevention with nirsevimab on infants’ #RSV hospitalizations in Belgium
"Savings in health care resources were observed with ⏬ lenght of stay, invasive ventilatory support and nutritional support"
#IDSky
link.springer.com/article/10.1...
Background Since 2023, two preventive tools (monoclonal antibodies, nirsevimab, and preF maternal vaccine) were approved to protect infants against severe RSV infections. During winter 2024–2025, nirs...
